logo-loader

EMV Capital: refinanced and focused on enhancing value

Last updated: 18:11 16 Nov 2026 AEDT, First published: 23:11 04 Jun 2021 AEST

Snapshot

  • EMV Capital's AMR Bio receives supportive feedback for phase III design of infection-prevention gel
NetScientific PLC -

About the company

EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.

How it is doing

16 Nov 2026

EMV Capital (AIM:EMVC) said its portfolio company AMR Bio has received supportive feedback from US regulators on the design of a late-stage trial for its nasal gel XF-73.

The Food and Drug Administration (FDA) backed the proposed phase III design at an end-of-phase II meeting and made recommendations that will shape the final trial plans.

AMR Bio expects to submit full protocols for its two planned pivotal trials to the FDA in the coming months.

XF-73 is a gel applied inside the nose in the 24 hours before surgery to clear Staphylococcus aureus bacteria, including the drug-resistant superbug MRSA, and so prevent post-operative wound infections.

14 Oct 2026

Wall Street ended lower on Tuesday as continued pressure on chipmakers and selling in large-cap healthcare and technology stocks weighed on the major indexes.

The Dow Jones Industrial Average fell 180 points, or 0.4%, to 51,670, while the S&P 500 slipped 2 points to 7,805. The Nasdaq Composite lost 42 points, or 0.2%, to 27,204.

25 Sep 2026

Panmure Liberum has trimmed its price target on EMV Capital (AIM:EMVC, FRA:NTK1) to 128p from 132p, but stuck with a "buy" call, arguing that a pair of portfolio spin-outs will leave the growth capital investor's accounts far easier to read.

The broker sees more than 160% upside from the current 48.5p, with the shares trading at a roughly 57% discount to its estimated sum-of-the-parts valuation.

XanaMIA results: What's next for Actinogen Medical?

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged...

9 hours, 43 minutes ago